Jpmorgan Chase & CO Spruce Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 72 shares of SPRB stock, worth $33. This represents 0.0% of its overall portfolio holdings.
Number of Shares
72
Previous 11
554.55%
Holding current value
$33
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SPRB
# of Institutions
42Shares Held
16.9MCall Options Held
26.9KPut Options Held
59.3K-
River Vest Venture Management LLC St. Louis, MO2.94MShares$1.35 Million22.27% of portfolio
-
Carlyle Group Inc. Washington, DC2.9MShares$1.33 Million0.18% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.61MShares$1.2 Million0.04% of portfolio
-
Abingworth LLP London, X01.79MShares$824,5580.65% of portfolio
-
Acadian Asset Management LLC Boston, MA1.37MShares$629,2780.0% of portfolio
About SPRUCE BIOSCIENCES, INC.
- Ticker SPRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,560,200
- Market Cap $10.8M
- Description
- Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...